A randomized multicenter study with non-inferiority hypothesis, comparing the availability to maintain a complete viral suppression by a monotherapy of darunavir/r [ritonavir] to a NRTI [nucleoside reverse transcriptase inhibitor] containing regimen including darunavir/r, in HIV-1 infected patients with previous prolonged complete viral suppression. ANRS 136 MONOI

Trial Profile

A randomized multicenter study with non-inferiority hypothesis, comparing the availability to maintain a complete viral suppression by a monotherapy of darunavir/r [ritonavir] to a NRTI [nucleoside reverse transcriptase inhibitor] containing regimen including darunavir/r, in HIV-1 infected patients with previous prolonged complete viral suppression. ANRS 136 MONOI

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Darunavir (Primary) ; Nucleoside reverse transcriptase inhibitors; Ritonavir; Saquinavir
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms MONOI
  • Most Recent Events

    • 26 Jul 2017 Results (n=637) of pooled analysis of NCT00140751, NCT00421551, NCT00946595 trials analysing distribution of ultrasensitive viral load (USVL) and impact of USVL on virological failure presented at the 9th International AIDS Society Conference on HIV Science
    • 10 Jun 2017 Biomarkers information updated
    • 07 Dec 2011 Primary endpoint 'Viral-load' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top